2022
IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas
McQuaid DC, Katz SG, Xu ML. IRF8 as a Novel Marker to Differentiate Between CD30-Positive Large Cell Lymphomas. American Journal Of Clinical Pathology 2022, 158: 173-176. PMID: 35460405, PMCID: PMC10664184, DOI: 10.1093/ajcp/aqac044.Peer-Reviewed Original Research
2019
ALCL by any other name: the many facets of anaplastic large cell lymphoma
Irshaid L, Xu ML. ALCL by any other name: the many facets of anaplastic large cell lymphoma. Pathology 2019, 52: 100-110. PMID: 31706671, DOI: 10.1016/j.pathol.2019.09.007.Peer-Reviewed Original ResearchMeSH KeywordsDiagnosis, DifferentialGene RearrangementHumansLymphoma, Large-Cell, AnaplasticPhenotypePrognosisReceptor Protein-Tyrosine KinasesConceptsAnaplastic large cell lymphomaAnaplastic lymphoma kinaseALK gene translocationALK(-) ALCLLarge cell lymphomaALK gene rearrangementVariable prognosisFavorable prognosisCell lymphomaGene rearrangementsNon-Hodgkin T-cell lymphomaExtent of diseaseLarge lymphoma cellsT-cell lymphomaGene translocationSpecific gene rearrangementsPatient demographicsIntermediate prognosisDismal prognosisImmunohistochemical phenotypeClinical behaviorFavorable outcomeDifferential diagnosisImplant placementSkin lesions